Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8501740
Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
granted -
US 8501705
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
granted -
US 8501692
Compositions and methods for altering cocaine esterase activity
granted -
US 8501423
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
granted -
US 8501194
Vaccine for viruses that cause persistent or latent infections
granted -
US 8497307
Aryl guanidine F1F0-ATPase inhibitors and related methods
granted -
US 8497258
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8497241
WNT10-derived peptide and use thereof
granted -
US 8496957
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
granted -
US 8492347
Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
granted -
US 8491890
Methods and compositions for inhibiting diseases of the central nervous system
granted -
US 8491883
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
granted -
US 8486410
RLIP76 liposomes for protection against irradiation
granted -
US 8487077
Simplified one-pot synthesis of [18F]SFB for radiolabeling
granted -
US 8486423
Thermo-kinetic mixing for pharmaceutical applications
granted -
US 8486981
Selective ligands for the dopamine 3 (D3) receptor and methods of using the same
granted -
US 8486909
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
granted -
US 8486428
Compositions and methods for making and using acyclic N-halamine-based biocidal polymeric materials and articles
granted -
US 8486385
Methods for therapy of neurodegenerative disease of the brain
granted -
US 8486391
Cancer treatment kits using antibodies to aminophospholipids
granted -
US 8486370
Heterocyclic ligands for integrin imaging and therapy
granted -
US 8481757
Compounds and compositions useful in the treatment of malaria
granted -
US 8481005
Methods to prevent cytotoxicity using N-acetyl-cysteine
granted -
US 8481313
Retinal pigment epithelial stem cells
granted -
US 8481024
Vaccines against tularemia
granted -
US 8481478
Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
granted -
US 8481529
Combination cancer chemotherapy
granted -
US 8481507
Micro-RNAs that control myosin expression and myofiber identity
granted -
US 8481311
Progenitor cells from wharton's jelly of human umbilical cord
granted -
US 8480637
Nanochanneled device and related methods
granted -
US 8475792
Molecules with extended half-lives, compositions and uses thereof
granted -
US 8476451
Tubulysin D analogues
granted -
US 8476043
Inhibitors for the soluble epoxide hydrolase
granted -
US 8474529
Control of concentric tubing direction
granted -
US 8470528
Methods and compositions related to adenoassociated virus-phage particles
granted -
US 8470976
Methods and compositions for targeting macromolecules into the nucleus
granted -
US 8470545
Methods of modulating cold sensory perception via a cold- and menthol-sensitive receptor (CMR1)
granted -
US 8470520
Decellularization and recellularization of organs and tissues
granted -
US 8465755
Recombinant bacterium capable of eliciting an immune response against enteric pathogens
granted -
US 8466154
Methods and compositions related to wrapping of dehydrons
granted -
US 8465737
Three-dimensional structure of complement receptor type 2 and uses thereof
granted -
US 8461298
Compositions and methods for modification of biomolecules
granted -
US 8461153
Benzodiazepinone compounds useful in the treatment of skin conditions
granted -
US 8460651
Methods of treating amyotrophic lateral sclerosis (ALS)
granted -
US 8460653
Superoxide dismutase variants and methods of use thereof
granted -
US 8460713
Administration of cells and cellular extracts for rejuvenation
granted -
US 8455553
Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease and transplant rejection
granted -
US 8455621
Influenza A virus vaccines and inhibitors
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory